BridgeBio to Present Key Phase 1 Clinical Data of 'BBT-176' at World Conference on Lung Cancer in August

[Asia Economy Reporter Lee Gwanju] Bridge Biotherapeutics announced on the 4th that it plans to present the key data of the Phase 1 clinical trial of the next-generation non-small cell lung cancer (NSCLC) drug candidate 'BBT-176' orally at the World Conference on Lung Cancer to be held in August.

The World Conference on Lung Cancer is the largest academic conference specializing in lung cancer and other thoracic malignancies, with experts participating from over 100 countries worldwide. This year's conference will be held from August 6 to 9 (local time) in Vienna, Austria.

According to the interim results of the BBT-176 Phase 1 clinical trial previously disclosed by Bridge Biotherapeutics, among the 16 cumulative subjects, 6 have taken BBT-176 for 2 cycles (6 weeks) or more without further disease progression or are continuing the treatment. Two subjects were observed radiologically to have tumor size reductions of 51% and 30%, respectively, which were confirmed as cases of partial response (PR).

The patient with the largest tumor size reduction (51%) was identified as carrying a triple mutation including C797S, and the company explained that this confirmed significant antitumor activity of BBT-176 in C797S-positive triple mutations targeted by the drug.

Lee Jung-kyu, CEO of Bridge Biotherapeutics, stated, “Alongside the clinical trial of BBT-176, we are also assessing the clinical value of liquid biopsy for companion diagnostics and treatment response confirmation, adding innovation to the development of next-generation lung cancer therapies. We will strive to provide new treatment options for non-small cell lung cancer through the development of BBT-176 and other anticancer pipelines.”

This content was produced with the assistance of AI translation services.